title: Protective effects of indomethacin and cyclophosphamide but not of infliximab on liver metabolic changes caused by adjuvant-induced arthritis.
abstract: In the study, indomethacin, cyclophosphamide, and infliximab were administered to adjuvant-induced arthritic rats to determine if they were able to prevent the abnormalities caused by arthritis on hepatic metabolism. The drugs were administered to arthritic rats, and at the clinical onset of arthritis (day 14 after adjuvant injection), the livers were perfused to evaluate gluconeogenesis, ureagenesis, oxygen uptake, L: -lactate, pyruvate, and ammonia release from L: -alanine. The effects of the drugs on body weight gain and the signs of arthritis (paw edema, appearance of secondary lesions, and weights of lymphoid tissues) were also evaluated. Cyclophosphamide could completely prevent liver metabolic changes and the inflammatory response. Indomethacin restored ureagenesis, minimized the decrease in gluconeogenesis, and exerted a partially beneficial effect on inflammatory reactions. Infliximab did not improve arthritis-induced liver metabolic alterations or inflammatory responses. These results suggest the participation of prostaglandins, but not TNF-α, on arthritis-induced liver metabolic alterations.
authors.affiliation: Department of Pharmacy and Pharmacology, University of Maringá, Bloco K68-106, Avenida Colombo, 5790, CEP: 87020-900, Maringá, Paraná, Brazil.
authors.forename: Maria Angélica Raffaini Covas Pereira
authors.initials: MA
authors.lastname: da Silva
authors.forename: Ciomar Aparecida
authors.initials: CA
authors.lastname: Bersani-Amado
authors.forename: Emy Luiza
authors.initials: EL
authors.lastname: Ishii-Iwamoto
authors.forename: Lívia
authors.initials: L
authors.lastname: Bracht
authors.forename: Silvana Martins
authors.initials: SM
authors.lastname: Caparroz-Assef
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000378:metabolism; D003520:Cyclophosphamide / Q000494:pharmacology* / Q000627:therapeutic use; D007213:Indomethacin / Q000494:pharmacology* / Q000627:therapeutic use; D007249:Inflammation; D000069285:Infliximab; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D011453:Prostaglandins; D020011:Protective Agents; D051381:Rats; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000911:Antibodies, Monoclonal; D011453:Prostaglandins; D020011:Protective Agents; D014409:Tumor Necrosis Factor-alpha; D003520:Cyclophosphamide; D000069285:Infliximab; D007213:Indomethacin